DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Tobramycin is a drug marketed by Alcon Pharms Ltd, Alembic Pharms Ltd, Apotex Inc, Bausch And Lomb, Fera Pharms, Gland Pharma Ltd, Somerset Theraps Llc, Akorn, Alkem Labs Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Lupin, Mylan, Sun Pharm, Teva Pharms Usa, Apothecon, Baxter Hlthcare Corp, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Mylan Labs Ltd, Watson Labs Inc, West-ward Pharms Int, Xellia Pharms Aps, and Xgen Pharms. and is included in forty-eight NDAs.
The generic ingredient in TOBRAMYCIN is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
A generic version of TOBRAMYCIN was approved as tobramycin sulfate by WEST-WARD PHARMS INT on April 26th, 1991.
Summary for TOBRAMYCIN
|Finished Product Suppliers / Packagers:||23|
|Raw Ingredient (Bulk) Api Vendors:||67|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for TOBRAMYCIN|
|Drug Sales Revenues:||Drug sales revenues for TOBRAMYCIN|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for TOBRAMYCIN|
|What excipients (inactive ingredients) are in TOBRAMYCIN?||TOBRAMYCIN excipients list|
|DailyMed Link:||TOBRAMYCIN at DailyMed|
Recent Clinical Trials for TOBRAMYCIN
Identify potential brand extensions & 505(b)(2) entrants
|University of Colorado, Denver||Phase 4|
|Denver Health and Hospital Authority||Phase 4|
|Joint Purification Systems||Phase 3|
Pharmacology for TOBRAMYCIN
|Drug Class||Aminoglycoside Antibacterial |